Cargando…

Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment

Combining immune checkpoint therapy (ICT) and targeted therapy holds great promises for broad and long-lasting anti-cancer therapies. However, combining ICT with anti-PI3K inhibitors have been challenging because the multifaceted effects of PI3K on both cancer cells and immune cells within the tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Zhi, Xu, Zihan, Zhang, Liuzhen, Zou, Yongkang, Li, Jinping, Yan, Wenyu, Li, Cheng, Liu, Ningshu, Wu, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748754/ https://www.ncbi.nlm.nih.gov/pubmed/35013322 http://dx.doi.org/10.1038/s41467-021-27833-0

Ejemplares similares

Combined targeting of G protein‐coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN‐null triple negative breast cancer
por: Zecchin, Davide, et al.
Publicado: (2020)

Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
por: Chandrasekaran, Sanjay, et al.
Publicado: (2021)

AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
por: Dunn, Shanade, et al.
Publicado: (2022)

Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition
por: Zhao, Manzhi, et al.
Publicado: (2023)

Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer
por: Su, Qingtai, et al.
Publicado: (2016)

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
por: Eschweiler, Simon, et al.
Publicado: (2022)

NFATc1 Promotes Prostate Tumorigenesis and Overcomes PTEN Loss-Induced Senescence
por: Manda, Kalyan R., et al.
Publicado: (2015)

Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer
por: Allott, Emma H., et al.
Publicado: (2018)

Age-Related Increased Onset and Progression of Prostate Cancer Is Revealed in Novel Pten-Null Mouse Models
por: Zhang, Qiuyang, et al.
Publicado: (2020)

Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1(+) prostate luminal cells
por: Kwon, Oh-Joon, et al.
Publicado: (2020)

Activation of hepatic stellate cell in Pten null liver injury model
por: He, Lina, et al.
Publicado: (2016)

The PTEN–PI3K Axis in Cancer
por: Papa, Antonella, et al.
Publicado: (2019)

Activated PI3Kδ breaches multiple B cell tolerance checkpoints and causes autoantibody production
por: Lau, Anthony, et al.
Publicado: (2019)

Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer
por: Wu, Ray-Chang, et al.
Publicado: (2019)

PRL-3 promotes the peritoneal metastasis of gastric cancer through the PI3K/Akt signaling pathway by regulating PTEN
por: Xiong, Jianbo, et al.
Publicado: (2016)

Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents
por: Degtyarev, Michael, et al.
Publicado: (2008)

Oncogenic signaling in amphiregulin and EGFR‐expressing PTEN‐null human breast cancer
por: Kappler, Christiana S., et al.
Publicado: (2014)

In renal cell carcinoma the PTEN splice variant PTEN-Δ shows similar function as the tumor suppressor PTEN itself
por: Breuksch, Ines, et al.
Publicado: (2018)

Modulating the tumor microenvironment via oncolytic virus and PI3K inhibition synergistically restores immune checkpoint therapy response in PTEN-deficient glioblastoma
por: Xing, Fan, et al.
Publicado: (2021)

Untargeted stable isotope-resolved metabolomics to assess the effect of PI3Kβ inhibition on metabolic pathway activities in a PTEN null breast cancer cell line
por: Lackner, Marcel, et al.
Publicado: (2022)

The dietary isothiocyanate sulforaphane modulates gene expression and alternative gene splicing in a PTEN null preclinical murine model of prostate cancer
por: Traka, Maria H, et al.
Publicado: (2010)

Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer
por: de Nóbrega, Monyse, et al.
Publicado: (2020)

Molecular Characterization of the Dominant-Negative Role of Cancer-Associated PTEN: Sometimes, Null is Better
por: Marchi, Saverio, et al.
Publicado: (2014)

PTEN regulation of the proliferation and differentiation of auditory progenitors through the PTEN/PI3K/Akt-signaling pathway in mice
por: Sun, Chen, et al.
Publicado: (2014)

Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
por: Uehara, Mayuko, et al.
Publicado: (2017)

Hyper-activated PI3K-δ in immunodeficiency
por: Heurtier, Lucie, et al.
Publicado: (2015)

The Treatment of Activated PI3Kδ Syndrome
por: Coulter, Tanya I., et al.
Publicado: (2018)

A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy
por: Xiang, Qiong, et al.
Publicado: (2021)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers
por: Zhang, Ailin, et al.
Publicado: (2023)

Imaging heterogeneity in the mitochondrial redox state of premalignant pancreas in the pancreas-specific PTEN-null transgenic mouse model
por: Xu, He N, et al.
Publicado: (2013)

PTEN regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression
por: Miller, Karina, et al.
Publicado: (2023)

Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma
por: Lee, Dae-Hee, et al.
Publicado: (2015)

Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells
por: Naguib, Adam, et al.
Publicado: (2018)

Precision Targeting of pten-Null Triple-Negative Breast Tumors Guided by Electrophilic Metabolite Sensing
por: Liu, Xuyu, et al.
Publicado: (2020)

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome
por: Rao, V. Koneti, et al.
Publicado: (2023)

Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas
por: Xie, Shaozhen, et al.
Publicado: (2020)

The orchestrated signaling by PI3Kα and PTEN at the membrane interface
por: Kotzampasi, Danai Maria, et al.
Publicado: (2022)

Double Deletion of PI3K and PTEN Modifies Lens Postnatal Growth and Homeostasis
por: Sellitto, Caterina, et al.
Publicado: (2022)

Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors
por: Yamada, Tomoharu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e9g93hict5tgmqhcuef5pounrp